Key result
Activation of the Mas receptor or administration of Ang-(1-7) or analogs is proposed as a potential therapeutic strategy to control the inflammatory response mediated by SARS-CoV-2.
Why the study?
Does activation of the Ang-(1-7)/Mas receptor pathway reduce inflammation and lung injury in patients with COVID-19?
Does activation of the Ang-(1-7)/Mas receptor pathway reduce inflammation and lung injury in patients with COVID-19?
Activating the Ang-(1-7)/Mas receptor pathway may counteract the deleterious pro-inflammatory and pro-thrombotic effects of ACE2 downregulation caused by SARS-CoV-2 infection.
The renin-angiotensin system is involved in the pathophysiology of inflammatory diseases through an increase in angiotensin converting enzyme (ACE)/angiotensin (Ang) II/AT1 receptor axis activity. It has been shown that ACE activity is increased in acute respiratory distress syndrome and there is a strong correlation between the level of ACE activity and the degree of lung injury. SARS-CoV-2, the new coronavirus that causes COVID-19, similar to other coronaviruses, was recently shown to use ACE2 as a receptor to get into host cells. However, it has been reported that most of the treatments that stimulates the ACE2/Ang-(1-7)/Mas axis induces beneficial effects, such as, antihypertensive, anti-inflammatory, anti-proliferative, anti-thrombotic and anti-fibrotic. Here we discussed the potential of activation of Ang-(1-7)/Mas pathway as strategy to treat COVID-19.
No takes yet. Share an insight, caveat, or question.
Magalhães et al. (2020) conducted an editorial in COVID-19 (SARS-CoV-2 infection). Ang-(1-7) or Mas receptor agonists was evaluated. Activation of the Mas receptor or administration of Ang-(1-7) or analogs is proposed as a potential therapeutic strategy to control the inflammatory response mediated by SARS-CoV-2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: